OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work

Crypto Insight Summary: The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients. Crypto Insight Analysis: Direction: Neutral Impact: No Impact Horizon: Short-term (1-3 days) Reasoning: AI drug development news has no direct impact on crypto markets.